After a disastrous phase I clinical trial last year that left six volunteers seriously injured, Britain’s Medicines and Healthcare Research Agency (MHRA) has tightened its clinical trial regulations. Now studies of certain classes of drugs that have never before been tested in humans will have to follow new guidelines on a range of topics, including dosing protocols and training for investigators.
